CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 570 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03933826
NCT03933826N/AActive

CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

University of Washington·observational·Posted May 1, 2019·Updated May 12, 2026

In Brief

An observational study for Bladder Cancer and 2 related conditions. Active but no longer recruiting, targeting 570 participants across 36 sites.

Detailed Summary

Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of non-muscle-invasive bladder cancer (NMIBC), and provide for personalized, patient-centered care. The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with Bacillus Calmette-Guerin (BCG) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/AActive
2020202120222023202420252026202720282029
First PostedMay 1, 2019
Enrollment StartJul 9, 2019
Primary CompletionJan 31, 2025
Study CompletionJun 30, 2029
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 7.2 years ago